Erasca, Inc. Stock-Based Compensation
Erasca, Inc. (ERAS) reported Stock-Based Compensation of $18.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- Erasca, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $9.61M, a 50.14% increase year-over-year.
- Erasca, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $8.46M, a 26.02% increase year-over-year.
- Erasca, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $5.82M, a 7.69% decline year-over-year.
- Erasca, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $5.96M, a 10.13% decline year-over-year.
- Erasca, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $24.90M, a 7.69% decline from fiscal 2024.
- Erasca, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $26.97M, a 2.83% increase from fiscal 2023.
- Erasca, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $26.23M, a 30.44% increase from fiscal 2022.
- Erasca, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $20.11M, a 141.38% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $18.07M 10-Q · filed 2026-08-11 | $23.89M derived: sum of 3 quarters · filed 2026-08-11 | $29.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $8.46M 10-Q · filed 2026-05-11 | $14.28M derived: sum of 2 quarters · filed 2026-05-11 | $20.25M derived: sum of 3 quarters · filed 2026-05-11 | $26.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $11.79M derived: sum of 2 quarters · filed 2026-03-12 | $18.19M derived: sum of 3 quarters · filed 2026-08-11 | $24.90M 10-K · filed 2026-03-12 |
| 2025-09-30 | $5.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $12.36M derived: sum of 2 quarters · filed 2026-08-11 | $19.08M 10-Q · filed 2025-11-12 | $25.38M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $13.11M 10-Q · filed 2026-08-11 | $19.42M derived: sum of 3 quarters · filed 2026-08-11 | $26.06M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $6.71M 10-Q · filed 2026-05-11 | $13.02M derived: sum of 2 quarters · filed 2026-05-11 | $19.66M derived: sum of 3 quarters · filed 2026-05-11 | $26.84M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $6.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $12.95M derived: sum of 2 quarters · filed 2026-03-12 | $20.13M derived: sum of 3 quarters · filed 2026-03-12 | $26.97M 10-K · filed 2026-03-12 |
| 2024-09-30 | $6.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $13.82M derived: sum of 2 quarters · filed 2025-11-12 | $20.66M 10-Q · filed 2025-11-12 | $26.80M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $7.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $14.03M 10-Q · filed 2025-08-12 | $20.16M derived: sum of 3 quarters · filed 2025-08-12 | $26.40M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $6.85M 10-Q · filed 2025-05-13 | $12.98M derived: sum of 2 quarters · filed 2025-05-13 | $19.22M derived: sum of 3 quarters · filed 2025-05-13 | $26.23M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $12.37M derived: sum of 2 quarters · filed 2025-03-20 | $19.39M derived: sum of 3 quarters · filed 2025-03-20 | $26.23M 10-K · filed 2025-03-20 |
| 2023-09-30 | $6.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $13.25M derived: sum of 2 quarters · filed 2024-11-12 | $20.09M 10-Q · filed 2024-11-12 | $25.48M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $7.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $13.86M 10-Q · filed 2024-08-12 | $19.24M derived: sum of 3 quarters · filed 2024-08-12 | $24.47M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $6.84M 10-Q · filed 2024-05-08 | $12.22M derived: sum of 2 quarters · filed 2024-05-08 | $17.46M derived: sum of 3 quarters · filed 2024-05-08 | $22.51M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $10.61M derived: sum of 2 quarters · filed 2024-03-27 | $15.67M derived: sum of 3 quarters · filed 2024-03-27 | $20.11M 10-K · filed 2024-03-27 |
| 2022-09-30 | $5.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $10.29M derived: sum of 2 quarters · filed 2023-11-09 | $14.73M 10-Q · filed 2023-11-09 | $17.61M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $9.50M 10-Q · filed 2023-08-10 | $12.38M derived: sum of 3 quarters · filed 2023-08-10 | $15.40M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $4.44M 10-Q · filed 2023-05-15 | $7.33M derived: sum of 2 quarters · filed 2023-05-15 | $10.34M derived: sum of 3 quarters · filed 2023-05-15 | $11.98M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $5.90M derived: sum of 2 quarters · filed 2023-03-23 | $7.54M derived: sum of 3 quarters · filed 2023-03-23 | $8.33M 10-K · filed 2023-03-23 |
| 2021-09-30 | $3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.65M derived: sum of 2 quarters · filed 2022-11-09 | $5.45M 10-Q · filed 2022-11-09 | $5.86M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.43M 10-Q · filed 2022-08-11 | $2.84M derived: sum of 3 quarters · filed 2022-08-11 | $3.01M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $795.00K 10-Q · filed 2022-05-12 | $1.20M derived: sum of 2 quarters · filed 2022-05-12 | $1.38M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $407.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $583.00K derived: sum of 2 quarters · filed 2022-03-24 | $797.00K 10-K · filed 2022-03-24 | |
| 2020-09-30 | $176.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $390.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $214.00K 10-Q · filed 2021-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |